These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35779497)

  • 1. Dry powder inhalers of antitubercular drugs.
    Nainwal N; Sharma Y; Jakhmola V
    Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
    Hanif SN; Garcia-Contreras L
    Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
    Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
    Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis.
    Aekwattanaphol N; Das SC; Khadka P; Nakpheng T; Ali Khumaini Mudhar Bintang M; Srichana T
    Int J Pharm; 2024 Oct; 664():124608. PubMed ID: 39163929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
    Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
    Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
    ElKasabgy NA; Adel IM; Elmeligy MF
    AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled dry powder formulations for treating tuberculosis.
    Das S; Tucker I; Stewart P
    Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
    Patil TS; Deshpande AS; Deshpande S; Shende P
    J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
    Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
    Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quest to deliver high-dose rifampicin: can the inhaled approach help?
    Khadka P; Dummer J; Hill PC; Das SC
    Expert Opin Drug Deliv; 2024; 21(1):31-44. PubMed ID: 38180078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment.
    Patil SM; Diorio AM; Kommarajula P; Kunda NK
    Int J Pharm; 2024 Mar; 653():123920. PubMed ID: 38387819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
    Srichana T; Eze FN; Thawithong E
    Drug Dev Ind Pharm; 2022 Oct; 48(10):528-538. PubMed ID: 36214588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uniformity and Efficacy of Dry Powders Delivered to the Lungs of a Mycobacterial-Surrogate Rat Model of Tuberculosis.
    Hirota K; Hirai Y; Nakajima T; Goto S; Makino K; Terada H
    Pharm Res; 2022 Jan; 39(1):143-152. PubMed ID: 34950976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.